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Objectives. This study sought to examine whether flow-
dependent dilation is impaired at the site of coronary artery
spasm in patients with coronary spastic angina.
Background. Physiologic stimuli such as exercise and exposure
to cold have been shown to cause an increase in coronary blood
flow, leading to flow-dependent dilation of coronary arteries in
normal subjects, but cause coronary constriction in patients with
coronary spastic angina.
Methods. A maximal increase in blood flow was induced
selectively in the left anterior descending coronary artery (LAD)
by infusion of adenosine through a Doppler flow catheter tip in the
midportion of the LAD in 10 patients with coronary spastic
angina, all with angiographically demonstrated spasm of the LAD,
and in 11 control patients. Coronary artery diameter at the
proximal site of the LAD (exposed to increased flow but not to
adenosine) was measured by quantitative angiography.
Results. Flow-dependent dilation of the proximal LAD was
found to be less in spasm arteries than in control arteries.
Infusion of NG-monomethyl-L-arginine (L-NMMA) in the proxi-
mal LAD suppressed flow-dependent dilation in control arteries
but had no significant effect on spasm arteries. The dilator
response to nitroglycerin was not impaired in spasm coronary
arteries.
Conclusions. Our results indicate that flow-dependent coronary
dilation is impaired in spasm arteries, partly due to a deficiency in
endothelial nitric oxide bioactivity, which in turn may contribute
to the increase in coronary tone during physiologic stimuli in
patients with coronary spastic angina.
(J Am Coll Cardiol 1997;30:920–6)
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Coronary artery spasm has been shown (1,2) to play an
important role not only in the pathogenesis of variant angina,
but also of ischemic heart disease in general, including other
forms of angina pectoris, acute myocardial infarction and
sudden death. However, the precise mechanism by which
coronary spasm occurs remains unknown. Nitric oxide (NO) is
an important vasodilator and is produced from L-arginine by
way of the enzyme NO synthase (NOS) (3–7). Analogues of
L-arginine, such as NG-monomethyl-L-arginine (L-NMMA),
competitively inhibit NO production and have been widely
used to examine the NO pathway in animals and humans
(6–13). The constitutive NOS in the arterial endothelium
continuously generates NO, which has been shown (8–14) to
maintain basal vascular tone in animals and humans. We
recently showed (14) that there is a deficiency in endothelial
NO bioactivity at the sites of coronary artery spasm and that
this deficiency plays an important role in the pathogenesis of
coronary spasm. Flow-dependent vasodilation is well known to
have an important role in the regulation of arterial tone
(15–19). Physiological stimuli, such as exercise and the cold
pressor test, which induce an increase in coronary blood flow,
have been shown (20–23) to dilate coronary arteries in normal
subjects. However, we and others have shown (1,2,24,25) that
spastic coronary arteries have increased basal tone and do not
dilate but constrict during exercise and exposure to cold. An
increase in blood flow or shear stress has been shown (3–
13,26,27) to produce endothelial release of NO, which causes
flow-dependent vasodilation. Thus, the present study aimed to
examine whether flow-dependent dilation is impaired at the
sites of coronary artery spasm in patients with coronary spastic
angina and to determine the possible relevance of deficient NO
bioactivity to the abnormal response of coronary tone to blood
flow in spasm coronary arteries.
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Methods
Study patients. The study included 10 patients with coro-
nary spastic angina (mean age 59 years, range 43 to 71; six men,
four women) who fulfilled the following inclusion criteria: 1)
spontaneous chest pain in association with ST segment eleva-
tion or depression on the 12-lead electrocardiogram (ECG) or
the ambulatory ECG at rest, usually in the middle of the night
or early morning and more than two times a day during the
study; 2) coronary spasm (total or subtotal occlusion) of the
left anterior descending coronary artery (LAD) demonstrated
angiographically during chest pain, with ST segment changes
after intracoronary injection of acetylcholine (ACh), as previ-
ously reported (28,29); 3) no organic coronary artery stenosis
on angiography. Five patients had transient ST segment ele-
vation and five ST segment depression during the spontaneous
attacks. All 10 patients with coronary spastic angina performed
treadmill exercise and hyperventilation tests. Anginal attacks
of chest pain with ST segment changes occurred in two patients
during the treadmill test (ST segment elevation in one, ST
segment depression in the other) and in four during the
hyperventilation test (ST segment elevation in three, ST seg-
ment depression in one). The spontaneous attacks were
promptly resolved by the administration of sublingual nitro-
glycerin and were almost completely prevented by calcium
channel blocking agents in all 10 patients with coronary spastic
angina. In patients with coronary spastic angina, the proximal
LAD diameter at baseline angiography was .1.5 mm, so the
Doppler catheter was allowed to avoid catheter-induced coro-
nary spasm in these patients. All study patients had ambulatory
ECG monitoring for at least 48 h. ST segment changes on
12-lead and ambulatory electrocardiography were considered
significant if transient ST segment elevation (.0.2 mV) or
depression (.0.1 mV) versus baseline levels occurred at 60 to
80 ms after the J point.
This study also included 11 control patients who underwent
diagnostic cardiac catheterization for evaluation of atypical
chest pain (mean age 57 years, range 39 to 70; eight men, three
women) and were matched for coronary artery disease risk
factors to patients with coronary spastic angina. The control
patients fulfilled the following inclusion criteria: 1) no signifi-
cant ST segment changes during chest pain on 12-leads and
ambulatory electrocardiography; 2) no chest pain or ST seg-
ment changes during treadmill and hyperventilation testing; 3)
angiographically normal coronary arteries and no coronary
spasm (,50% decrease in coronary diameter from baseline)
after intracoronary injection of ACh. Neither nitrates nor
calcium channel blockers were effective in relieving chest pain
in any control patient.
The clinical characteristics of the study patients are shown
in Table 1. All medications except sublingual nitroglycerin
were withdrawn at least 3 days before the study, and no patient
had taken nitroglycerin within 6 h of the study. No patient had
a previous myocardial infarction, congestive heart failure or
other serious diseases. Written informed consent was obtained
from all patients before the study. The study was approved by
the ethics committee of our institution.
Study protocol. Coronary angiography was performed with
the Judkins technique using contrast material (Ioxaglate,
Guerbet S.A.) in the morning when the patients were fasting.
After heart rate and blood pressure measurements, control
angiography of the left main and right coronary arteries was
performed. Thereafter, incremental doses of ACh were in-
jected into the left main coronary artery (20, 50 and 100 mg)
and subsequently into the right coronary artery (20 and 50 mg).
The method of injecting ACh for provocation of coronary
spasm has been detailed elsewhere (28,29). Coronary spasm
resolved spontaneously without the use of nitroglycerin in all
patients with coronary spastic angina in this study.
Flow-dependent dilation in human coronary arteries in vivo
was assessed similar to previously reported methods (18,19). In
brief, 15 min after completion of the intracoronary injection of
ACh, when systemic hemodynamic variables and angiographic
coronary artery diameters had returned to baseline levels, an
additional 5,000 U of heparin was given intravenously, and an
8F guiding catheter was positioned in the ostium of the left
main coronary artery. A 2.5F Doppler flow velocity catheter
(20-MHz pulsed Doppler catheter, Miller Instruments) was
positioned in the midportion of the LAD through the guiding
catheter over a guide wire. Flow velocity recordings were
referenced to zero and calibrated before introduction of the




LAD 5 left anterior descending coronary artery
LCx 5 left circumflex coronary artery
L-NMMA 5 NG-monomethyl-L-arginine
NO 5 nitric oxide
NOS 5 nitric oxide synthase







Age (yr) 59 6 11 57 6 10
Women/men 4/6 3/8
Total serum cholesterol (mg/dl) 181 6 36 191 6 33
HDL cholesterol (mg/dl) 39 6 8 46 6 14
Serum triglyceride (mg/dl) 127 6 69 140 6 41
Hypercholesterolemia† 0 1
Hypertension‡ 3 2
Diabetes mellitus§ 0 2
Current smokeri 2 4
*p 5 NS for all comparisons. †Total serum cholesterol $240 mg/dl. ‡Blood
pressure $140/90 mm Hg or taking antihypertensive medication. §Fasting blood
glucose $140 mg/dl or taking antidiabetic medication. i$10 cigarettes/day for
$10 years. Data presented are mean value 6 SD or number of patients. CSA 5
coronary spastic angina.
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velocity catheter was connected to a velocimeter (model
MDV-20, Miller Instruments) and then to a multichannel
oscillographic recorder (Nihon Kohden, Japan) and was care-
fully positioned to obtain a stable flow velocity signal. There-
after, the position and range gate control were not changed
during the study. Throughout the study, phasic and mean
coronary blood flow velocities, heart rates, aortic pressure
(through the guiding catheter) and 12-lead ECGs were contin-
uously monitored and were recorded just before each coronary
angiogram.
Baseline angiography of the left coronary artery was per-
formed after injection of 8 ml of contrast medium through the
guiding catheter. Five minutes later, adenosine (40 mg/kg body
weight per min at a rate of 2 ml/min) was infused into the
mid-portion of the LAD through the Doppler catheter tip.
This dose was chosen on the basis of a previous report (30)
showing that infusion of adenosine into the left main coronary
artery at a concentration .40 mg/kg per min elicited a maximal
increase in coronary blood flow with no change in systemic
hemodynamic variables. Angiography was again performed
60 s after the maximal increase in coronary blood flow (90 to
120 s after the start of the infusion), according to previous
reports (31,32) showing the time course of the maximal
increase in coronary blood flow and maximal flow-dependent
coronary dilation. Special care was taken to avoid uninten-
tional injection of adenosine into the proximal portion of the
LAD. The adenosine infusion was stopped just after angiog-
raphy, and a 10-min rest period was allowed for return of
coronary artery diameter and coronary blood flow to basal
levels, as confirmed by angiography and measurement of blood
flow. Thereafter, the guiding catheter was filled with L-NMMA
solution, and L-NMMA was infused into the ostium of the left
main coronary artery through the guiding catheter (50 mmol/
min for 4 min at a rate of 2 ml/min). Measurement of coronary
and systemic hemodynamic variables and coronary angiogra-
phy were performed during the last 30 s of the infusion.
Subsequently, adenosine infusion was repeated, and coronary
angiography was performed in the same manner as during the
first adenosine infusion, before L-NMMA. After an additional
10 min, coronary angiography was performed before and 2 min
after an intravenous bolus injection of nitroglycerin (250 mg) in
multiple projections in all study patients. All drug solutions
were kept at 37°C.
Quantitative coronary angiography. Quantitative coronary
angiography was performed according to a previously validated
technique (14,29,33). Coronary angiograms were recorded in
the right and left anterior oblique positions with adequate
angulation to allow clear visualization of the left main coronary
artery during the study period. The relations among focal spot,
patient and height of the image tube were kept constant during
the angiographic study. Measurement of the lumen diameter
of the coronary artery was performed quantitatively with the
use of a computer-assisted coronary angiographic analysis
system by two observers (M.O., S.S.) who had no knowledge of
the study protocol. The end-diastolic cine films that most
clearly visualized the coronary segments were videodigitized
and stored in a cardiac image analysis system (Cardio 500,
Kontron Instruments). Automated contour detection was per-
formed by the geometric edge differentiation technique de-
scribed in previous validation studies (14,29,33). The size of
the Judkins or guiding catheter was used to calibrate arterial
diameters (in mm); coronary segments analyzed were ;10 mm
long.
The sites at which the coronary artery diameter was mea-
sured were chosen according to previous reports (18,19) and
are depicted in the diagram of the LAD shown in Figure 1. In
brief, a segment of the LAD that was positioned between the
orifices of the first and second septal branches and was at least
10 mm proximal to the Doppler catheter tip was analyzed for
flow-mediated effects (proximal LAD). This segment was ex-
posed to L-NMMA and changes in blood flow but was not
exposed to adenosine. A segment of the LAD 20 mm distal to
the Doppler catheter tip (distal LAD) was analyzed for the
effects of adenosine and L-NMMA. A midsegment of the left
circumflex coronary artery (mid-LCx) was exposed to L-
NMMA but not to changes in blood flow or adenosine and
served as the control vessel. A segment of the LAD at the
Doppler catheter tip was analyzed to allow estimation of
volume flow from flow velocity measurements. All segments
were analyzed at each angiogram, and the responses of
the coronary diameters to the first adenosine infusion, the
L-NMMA infusion and the nitroglycerin injection were ex-
pressed as the percent change in coronary diameter from that
at angiography performed just before each infusion. The
response to the second adenosine infusion was expressed as
the percent change in diameter from that after the L-NMMA
infusion. Analysis of intraobserver and interobserver variability
for measurement of coronary artery diameter showed high
reproducibility (r 5 0.99, SEE 5 0.05 mm, p , 0.001 and r 5
0.99, SEE 5 0.04 mm, p , 0.001, respectively).
Coronary blood flow measurements. Estimates of blood
flow were calculated by multiplying the mean Doppler-derived
blood flow velocity by the cross-sectional area of the arterial
segment at the Doppler catheter tip. Cross-sectional area was
calculated from measurements of the coronary diameter, as-
suming a circular shape. The response of the coronary blood
Figure 1. Schematic representation of assessment for flow-dependent
dilation in the LAD.
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flow to the intracoronary infusion of various drugs was ex-
pressed as the percent change in blood flow from that just
before each infusion.
Drugs. L-NMMA and adenosine were obtained from Wako
Chemicals (Osaka, Japan) and were dissolved in physiologic
saline and sterilely filtered before use.
Statistical analysis. Results are expressed as mean value 6
SD, unless otherwise indicated. Differences between two mean
values were compared by a paired or unpaired Student t test.
Changes in systemic hemodynamic variables, proximal and
distal LAD diameters and coronary blood flow in response to
the various agents were statistically analyzed by repeated
measures analysis of variance, followed by the Bonferroni
comparison test. Correlation between the increase in blood
flow and the dilator response of the proximal LAD during the
adenosine infusion was examined by linear regression analysis.
A value of p , 0.05 was considered statistically significant.
Results
Provocation of coronary spasm. Coronary spasm was de-
fined as total or subtotal occlusion of the epicardial coronary
arteries associated with signs of myocardial ischemia such as
chest pain and ischemic ST segment changes. Spasm was
angiographically demonstrated by intracoronary injection of
ACh in the LAD of all patients with coronary spastic angina.
Coronary spasm was also demonstrated in four LCx and seven
right coronary arteries in patients with coronary spastic angina.
Coronary spasm in the LAD was documented at the proximal
segment in three patients with coronary spastic angina, and
subtotal occlusion occurred diffusely from the proximal to the
distal segments in the remaining seven. In contrast, intracoro-
nary injection of ACh did not induce coronary spasm in any
control patient.
Systemic hemodynamic variables and coronary blood flow.
As shown in Table 2, infusion of adenosine and L-NMMA did
not affect systemic hemodynamic variables either in patients
with coronary spastic angina or in control patients. There was
no significant difference in basal coronary blood flow between
spasm and control arteries (22 6 8 vs. 25 6 10 ml/min,
respectively). Adenosine infusion increased coronary blood
flow in both spasm and control arteries, but there was no
significant difference in percent increase in flow from baseline
values between spasm and control coronary arteries (percent
increase in flow: 540 6 350 vs. 520 6 260, respectively).
L-NMMA infusion had no effect on the increase in flow in
response to the second adenosine infusion in both spasm and
coronary arteries, and there was no significant difference in
percent increase in flow from values measured just before the
second adenosine infusion, after L-NMMA, between spasm
and control coronary arteries (percent increase in flow: 550 6
410 vs. 520 6 370, respectively).
Flow-dependent dilation of the proximal LAD. The base-
line diameter of the proximal LAD in spasm arteries was
significantly smaller than that in control arteries (2.0 6 0.2 vs.
2.5 6 0.5 mm, respectively, p , 0.02). The proximal segment of
the LAD dilated in response to the increase in flow in both
spasm and control coronary arteries, but the dilator response
was significantly less in spasm than in control arteries (Fig. 2).
There was a significantly positive correlation between the
increase in coronary blood flow and the dilator response of the
proximal LAD in control but not in spasm coronary arteries
(Fig. 3). Infusion of L-NMMA alone decreased the basal
diameter in control coronary arteries but had less effect in
spasm than in control arteries (Fig. 4). L-NMMA inhibited the
dilator response of the proximal LAD to the increase in flow
during the second adenosine infusion in control coronary
arteries but had minimal effect in spasm coronary arteries (Fig.
2). The mid-LCx did not change significantly in response to
adenosine infusion in both patients and control subjects (2.0 6
0.6 and 2.2 6 0.4 mm before adenosine vs. 2.1 6 0.7 and 2.1 6
0.4 mm after adenosine, respectively), excluding the potential
effect of the injected contrast material itself and that of the
recirculating adenosine.
Effect of adenosine on the distal LAD. The distal LAD
dilated in response to infusion of adenosine in both spasm and
control arteries, but there was no significant difference in
Figure 2. Flow-dependent dilation of the proximal LAD (mean 6 SD
percent increase in arterial diameter from control values) before and
after L-NMMA infusion in spasm (solid circles) and control coronary
arteries (open circles).






Pts with CSA 74 6 10 72 6 10 69 6 9 67 6 8 72 6 5
Control pts 74 6 14 76 6 13 72 6 11 69 6 11 81 6 17
MAP (mm Hg)
Pts with CSA 104 6 15 108 6 23 111 6 17 119 6 26 83 6 25*
Control pts 93 6 11 95 6 11 96 6 10 104 6 11 81 6 15*
*p , 0.01 versus baseline. Data presented are mean value 6 SD. CSA 5
coronary spastic angina; HR 5 heart rate; L-NMMA 5 NG-monomethyl-L-
arginine; NTG 5 nitroglycerin; Pts 5 patients; MAP 5 mean arterial pressure.
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percent increase in coronary diameters from control values
before and after L-NMMA infusion in the spasm and control
coronary arteries (before L-NMMA: 19.6 6 10.1 vs. 22.2 6
6.5 mm; after L-NMMA: 20.5 6 12.7 vs. 21.8 6 9.0, respectively
p 5 NS).
Dilator response to nitroglycerin. Nitroglycerin dilated the
proximal and distal segments of the LAD in both spasm and
control arteries. Figure 4 shows that the dilator response to
nitroglycerin was significantly greater in spasm arteries than in
control arteries. After nitroglycerin administration, the spasm
artery diameters were not different from those of the control
arteries (2.9 6 0.6 vs. 3.1 6 0.7 mm for the proximal LAD;
2.1 6 0.5 vs. 1.9 6 0.5 mm for the distal LAD, respectively, p 5
NS).
Discussion
The present study shows that dilation of the epicardial
coronary arteries in response to increased blood flow was
impaired in patients with coronary spastic angina compared
with that in control subjects. Because the response to nitro-
glycerin, a smooth muscle dilator, was not impaired in patients
with coronary spastic angina, and the magnitude of the in-
crease in the flow response to adenosine was comparable
between two groups of patients, impairment of flow-dependent
dilation appears to be due to endothelial vasodilator dysfunc-
tion. The present study also demonstrated that L-NMMA
suppressed flow-dependent dilation in control coronary arter-
ies but had minimal effect in spasm coronary arteries. It has
been shown (3–13,26,27) that an increase in blood flow or
shear stress induces endothelial release of NO, which causes
flow-dependent vasodilation. The present results therefore
indicate that endothelial-derived NO bioactivity may contrib-
ute at least in part to flow-dependent dilation in human
coronary arteries and that the NO bioactivity in response to an
increase in flow may be decreased in spasm coronary arteries.
Basal tone and NO activity. Moncada et al. (9) demon-
strated that removal of basal NO-mediated vasodilation of the
vascular system in an in vivo rat model leads to supersensitivity
to an exogenous nitrovasodilator. The present study showed
that infusion of L-NMMA alone constricted control coronary
arteries at baseline but had less effect on spasm coronary
arteries. Furthermore, the vasodilator response to nitroglyc-
erin was increased in the spasm arteries compared with control
arteries. The present study also showed that the diameter of
the spasm coronary arteries was smaller at baseline but was
comparable to control arteries after nitroglycerin administra-
tion, indicating that basal tone may be increased in spasm
coronary arteries, although the present study excluded patients
with coronary spastic angina who had highly increased basal
tone of the LAD. These results are in agreement with those of
previous reports by us (14) and Moncada et al. (9) and suggest
that basal NO bioactivity may be decreased in spasm coronary
arteries, leading to a supersensitive dilator response to exoge-
nous nitrovasodilators and to increased basal coronary tone.
Egashira et al. (34) recently reported that NO bioactivity was
preserved in the spasm coronary arteries of eight patients with
coronary spastic angina, which does not agree with our present
and previous (14) results. As shown in our and other previous
reports (1,35–37), the hyperreactivity of not only the spasm
sites but also the entire coronary arteries to the constrictor
effects of ACh as well as the dilator effects of nitrates is a
Figure 3. Correlation between percent in-
crease from control values in coronary blood
flow and the proximal LAD diameter of con-
trol (left panel) and spasm (right panel) cor-
onary arteries during adenosine infusion and
before L-NMMA infusion.
Figure 4. Percent changes (mean 6 SD) from control values in
proximal LAD diameter in response to intracoronary infusion of
L-NMMA alone (left panel) and nitroglycerin injection (right panel) in
spasm (solid circles) and control coronary arteries (open circles).
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characteristic feature of spasm coronary arteries without or-
ganic stenosis. Spasm frequently occurs in multiple coronary
arteries in patients with coronary spastic angina (36). However,
in the report by Egashira et al. (34), the coronary artery
diameter response to L-NMMA at the spastic sites was com-
pared with that at adjacent sites in the same spasm artery in
each patient. Furthermore, they did not compare the response
to L-NMMA in each segment of spasm coronary arteries with
that in the corresponding segment of the control coronary
arteries, even though the coronary artery diameter response to
L-NMMA has been reported (11,14) to vary within segments of
the coronary artery. Thus, differences in the method of analysis
and the limited number of the study patients in the report by
Egashira et al. (34) may explain in part the discrepancies
between our results and theirs.
Possible mechanisms. It has been shown (3–13,26,27) that
several agonists, as well as shear stress or blood flow, induce
production and release of NO in the normal vascular endothe-
lium. We previously showed (14) that NO bioactivity is also
deficient during stimulation with ACh in the spasm coronary
arteries of patients with coronary spastic angina. Therefore,
both our present and previous studies suggest that the defi-
ciency in NO bioactivity is unlikely to be dependent on the type
of stimulation; rather, dysfunction of NOS itself or the intra-
cellular regulatory pathway to endothelial NOS activation,
mediated by different types of stimulation, may possibly con-
tribute to deficient NO bioactivity in the spasm coronary
artery. Increases in blood flow have been shown (38) to induce
endothelial release of vasodilators such as prostacyclin in
addition to NO. It is thus possible that a decrease in prosta-
cyclin release may also be involved in the mechanism of the
impairment of flow-dependent dilation of the spasm coronary
arteries. Also, the possibility of an increased breakdown of NO
by the increased presence of superoxide anions, as previously
reported (38), cannot be excluded. The present study shows
that the dilator response of the distal LAD to adenosine
infusion was comparable between the spasm and control
coronary arteries, and L-NMMA infusion had no significant
effect on the increase in the flow response to adenosine in
either the control or the spasm coronary arteries. Although it
has been reported (40) that endothelial NO may partly con-
tribute to adenosine-induced vasodilation in vitro, smooth
muscle dilation mediated by adenosine receptors present in
smooth muscle tissue may play a predominant role in
adenosine-induced coronary dilation (40,41).
NO deficiency does not seem to be caused by decreased
availability of L-arginine for NO synthesis. In our previous
report (14), we showed that intracoronary infusion of an excess
of L-arginine had no effect on the diameter of spasm coronary
arteries. Flow-dependent dilation and NO bioactivity have
been reported (12,18,19) to be impaired in the presence of
coronary risk factors, even though apparent atherosclerotic
changes were angiographically absent. However, this possibil-
ity is unlikely to explain the impairment of flow-dependent
dilation and the deficiency in NO bioactivity in patients with
coronary spastic angina. The present study was designed to
avoid this influence by matching the risk factors of patients
with coronary spastic angina with those of control subjects. It
was recently reported (42) that flow-dependent coronary dila-
tion in patients with normal coronary angiograms was not
significantly affected by infusion of L-NMMA, in contrast to the
present results. The report (42) did not describe the coronary
risk factors of the study patients or specify the coronary artery
segments analyzed for flow response, both of which impor-
tantly affect NO bioactivity in the coronary arteries (11,14),
and did not examine the coronary arteries studied for the
presence of spasm. Because angiograms underestimate the
extent of atherosclerosis (43), the pathologic presence of
coronary atherosclerosis cannot be excluded as an explanation
for the failure to show the contribution of NO to flow-
dependent dilation (42).
Clinical implications. Physiologic stimuli, such as exercise
and exposure to cold, which increase coronary blood flow, have
been shown to dilate coronary arteries in normal patients
(20–23) but cause coronary constriction in patients with coro-
nary spastic angina (1,2,24,25). The present results indicate
that flow-dependent coronary dilation is impaired in spasm
arteries at least in part because of a deficiency in endothelial
NO bioactivity, which in turn may contribute in part to an
increase in coronary tone during physiologic stimuli in patients
with coronary spastic angina.
Conclusions. The present study shows that endothelium-
dependent flow-mediated dilation is impaired in spasm coro-
nary arteries compared with that in control coronary arteries
and that L-NMMA inhibits flow-dependent dilation in control
coronary arteries but has minimal effect in spasm coronary
arteries. From these results, we conclude that endothelial
NO-mediated flow-dependent dilation is impaired in spasm
coronary arteries and that this impairment may play an impor-
tant role in the pathophysiology of coronary artery spasm in
patients with coronary spastic angina.
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